endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners UNITAID and the Transformational Investment Capacity (TIC) of MSF. 

Watch the two-minute animation

 

You can contact us, or follow us on Twitter.

endTB clinical trial partners announce completion of the Last Patient Last Visit

endTB participant and Dra Jimena Ruiz, Hospital Nacional Sergio Bernales, Lima, Peru

April 11, 2023

The endTB clinical trial, funded by global health agency Unitaid, has reached another milestone. The endTB consortium partners, Médecins Sans Frontières/Doctors Without Borders, Partners In Health and Interactive Research and Development are pleased to share that the last visit for the last study participant in the endTB trial was completed on 8 April.

The endTB consortium will now advance to the final stages of analyzing the study results. This trial is a critical step towards advancing viable, shorter, and more effective treatments for all patients with multidrug- or rifampin-resistant (MDR/RR) TB, including children, pregnant people, people living with important comorbidities such as HIV, hepatitis C, diabetes mellitus, and substance-use disorder. 

Read more

Clinical trial advancing treatment for deadly TB superbug reaches critical milestone

Anna Usova/MSF

[Press Release]

Paris/Boston, 24 March 2023 – This World Tuberculosis (TB) Day, the endTB-Q clinical trial marks a critical milestone as the final patient enrolls in the study. This first-of-its-kind clinical trial seeks to radically improve treatment for a strain of TB that is resistant to the most important standard medications, known as pre-extensively resistant (pre-XDR) TB.

By reaching full patient enrollment, the endTB consortium – made up of scientists and clinicians led by Médecins Sans Frontières/Doctors Without Borders (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD), with funding from global health agency Unitaid, MSF and PIH – is making significant advancements on the use of shorter and less toxic drug regimens.

Read more

PIH MSF MSF UNITAID Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo